aTyr Pharma (ATYR)
(Delayed Data from NSDQ)
$3.04 USD
-0.08 (-2.56%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $3.02 -0.02 (-0.66%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Atyr Pharma (ATYR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$19.40 | $35.00 | $9.00 | 521.79% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Atyr Pharma comes to $19.40. The forecasts range from a low of $9.00 to a high of $35.00. The average price target represents an increase of 521.79% from the last closing price of $3.12.
Analyst Price Targets (5 )
Broker Rating
Atyr Pharma currently has an average brokerage recommendation (ABR) of 1.20 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.20 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, four are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 80% and 20% of all recommendations. A month ago, Strong Buy made up 80%, while Buy represented 20%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 3 | 2 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.20 | 1.20 | 1.20 | 1.25 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
10/29/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
10/4/2024 | Wells Fargo Securities | Derek C Archila | Not Available | Strong Buy |
9/5/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
8/14/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
8/13/2024 | Piper Sandler | Yasmeen Rahimi | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.20 |
ABR (Last week) | 1.20 |
# of Recs in ABR | 5 |
Average Target Price | $19.40 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 89 of 252 |
Current Quarter EPS Est: | -0.22 |
ATYR FAQs
aTyr Pharma, Inc. (ATYR) currently has an average brokerage recommendation (ABR) of 1.20 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 5 brokerage firms.
The average price target for aTyr Pharma, Inc. (ATYR) is $19.40. The current on short-term price targets is based on 3 reports.
The forecasts for aTyr Pharma, Inc. (ATYR) range from a low of $9 to a high of $35. The average price target represents a increase of $538.16 from the last closing price of $3.04.
The current UPSIDE for aTyr Pharma, Inc. (ATYR) is 538.16%
Based on short-term price targets offered by five analysts, the average price target for Atyr Pharma comes to $19.40. The forecasts range from a low of $9.00 to a high of $35.00. The average price target represents an increase of 521.79% from the last closing price of $3.12.